Wird geladen...
Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
BACKGROUND: Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are recommended as the first-line therapy for chronic hepatitis B (CHB) due to their genetic barrier to resistance and effectiveness of virological suppression. TDF and ETV may cause renal toxicity through various mechanisms such as...
Gespeichert in:
| Veröffentlicht in: | Ther Clin Risk Manag |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5628694/ https://ncbi.nlm.nih.gov/pubmed/29033575 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S143286 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|